Year |
Citation |
Score |
2016 |
Alhazzazi TY, Alghamdi FT. Head and Neck Cancer in Saudi Arabia: a Systematic Review. Asian Pacific Journal of Cancer Prevention : Apjcp. 17: 4043-8. PMID 27644659 |
0.352 |
|
2016 |
Alhazzazi TY. Evaluation of Head and Neck Cancer Awareness and Screening Status in Jeddah, Saudi Arabia. Asian Pacific Journal of Cancer Prevention : Apjcp. 17: 1135-9. PMID 27039738 |
0.372 |
|
2016 |
Alhazzazi TY, Kamarajan P, Xu Y, Ai T, Chen L, Verdin E, Kapila YL. A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells. Anticancer Research. 36: 49-60. PMID 26722027 |
0.55 |
|
2013 |
Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. Sirtuin-3 (SIRT3) and the Hallmarks of Cancer. Genes & Cancer. 4: 164-71. PMID 24020007 DOI: 10.1177/1947601913486351 |
0.615 |
|
2012 |
Kamarajan P, Alhazzazi TY, Danciu T, D'silva NJ, Verdin E, Kapila YL. Receptor-interacting protein (RIP) and Sirtuin-3 (SIRT3) are on opposite sides of anoikis and tumorigenesis. Cancer. 118: 5800-10. PMID 22674009 DOI: 10.1002/Cncr.27655 |
0.576 |
|
2011 |
Alhazzazi TY, Kamarajan P, Verdin E, Kapila YL. SIRT3 and cancer: tumor promoter or suppressor? Biochimica Et Biophysica Acta. 1816: 80-8. PMID 21586315 DOI: 10.1016/J.Bbcan.2011.04.004 |
0.602 |
|
2011 |
Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, Kapila YL. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 117: 1670-8. PMID 21472714 DOI: 10.1002/Cncr.25676 |
0.606 |
|
2011 |
Kamarajan P, Alhazzazi T, D'Silva N, Verdin E, Kapila Y. Abstract 4768: Receptor interacting protein (RIP) and Sirtuin-3 (SIRT3) on opposite sides of anoikis resistance and promotes tumorigenesis Cancer Research. 71: 4768-4768. DOI: 10.1158/1538-7445.Am2011-4768 |
0.594 |
|
Show low-probability matches. |